AzTrials
AzTrials

Cardiovascular DiseaseNCT01606410

The Impact of Age and Fitness on Reperfusion Injury and Ischemic Preconditioning to Prevent This Injury

An observational study of Cardiovascular Disease, run by Radboud University Medical Center at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Rationale: Ischaemic preconditioning (IP) refers to the reduction of ischemia-reperfusion injury induced by a brief preceding period of ischemia. Also the arterial endothelium can be protected by IP. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Cardiovascular Disease
What is being tested?
IPC
How many people
30 participants
Where
1 siteNetherlands
Study dates
Apr 2011to Nov 2013
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Study population: Young sedentary volunteers (n=23, age 18-30), young active volunteers (n=23, age 18-30), older sedentary subjects (n=23, >55 years) and older physically active subjects (n=23, >55 years).

Who may be able to join

  • Healthy young volunteers : age 18-30
  • Healthy older volunteers: age >55 years
  • Sedentary: <1 h exercise per week
  • Trained: >5 h exercise per week
  • All subjects: written informed consent

Who cannot join

  • Smoking
  • History of any cardiovascular disease
  • Hypertension (in supine position: systole >140 mmHg, diastole >90 mmHg)
  • Diabetes Mellitus (fasting glucose >7.0 mmol/L or random glucose >11.0 mmol/L)
  • Hyperlipidaemia (fasting total cholesterol >6.5 mmol/L)
  • Chronic use of medication known to interfere with the cardiovascular system
  • Professional athletes
  • BMI >30 kg/m2

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • Department of Physiology

    Nijmegen, 6525 EX

Other trials in Netherlands

About this study

Official title: The Impact of Age and Fitness on Endothelial Reperfusion Injury and the Ability of Ischemic Preconditioning to Prevent This Injury

Rationale: Ischaemic preconditioning (IP) refers to the reduction of ischemia-reperfusion injury induced by a brief preceding period of ischemia. Also the arterial endothelium can be protected by IP. Several studies performed in animals and humans have demonstrated that the protective effects of IP are attenuated with aging. However, no previous study directly examined the underlying mechanisms of this observation. Possibly, the reduced protective effect of IP with aging relates to a direct effect on the endothelium, consequently leading to an attenuated ability of IP to prevent endothelial dysfunction after ischaemia reperfusion injury.

Several previous studies failed to demonstrate the ability of pharmacological stimuli to mimic the beneficial effects of IP in aged vessels. Restoration of the age-related reduction in effectiveness of IP may be possible through exercise training. In aged animals, physical training restores the efficacy of ischemic preconditioning. Indirect evidence indicates that physical activity, independent of other cardiovascular risk factors, protects against a occurrence as well as the severity of a myocardial infarction in humans. Although this suggests that physical activity may beneficially influence the age-related reduction in IP, no previous study provided direct evidence for this hypothesis.

Objective: To examine the impact of age and physical fitness on the ability of ischaemic preconditioning to protect endothelial damage in response to ischaemia reperfusion injury in healthy humans. A secondary objective is to explore the role of Toll-like receptor (TLR) signalling in the induction of IP in young and old subjects.

Read the detailed description

Cardiovascular disease has become a worldwide burden. In the Netherlands over 40.000 persons die annually due to coronary artery disease, either acute myocardial infarction or heart failure.1 Through plaque formation and negative vascular remodelling, significant stenotic lesions develop in the coronary arteries that subsequently limit coronary blood flow and ultimately can cause ischemic events. Reperfusion therapy (either pharmacologic, endovascular or surgical) is mandatory for salvage of ischemic tissue. However, during reperfusion several deleterious events take place causing further damage. Murry found that ischemia and reperfusion injury (IR-injury) could be reduced by a phenomenon called ischemic preconditioning.2 Short lasting repetitive episodes of ischemia prior to an ischemic event can induce tissue tolerance against IR-injury.

After discovery of this phenomenon, ample research has been devoted to elucidation of the underling protective mechanism, but also factors that improve or impair the ability of this phenomenon to protect arteries against ischaemia reperfusion injury. Several studies performed in animals and humans have demonstrated that the protective effects of IP are attenuated with aging. Much of this work has been performed in animal models or in human in vitro studies. Interestingly, no previous study directly examined the underlying mechanisms of this observation in humans using in vivo techniques. One potential explanation for an age-related reduction of the protective effect of IP relates to a direct effect on the endothelium.

Much scientific effort has been devoted to develop a human in vivo model to study ischemia and reperfusion injury. Recently, publications emerged using the flow mediated dilation (FMD) of the brachial or radial artery before and after a sustained ischaemic stimulus (20 minutes) to establish the presence of a blunted endothelial function after ischaemia reperfusion injury.3, 4 This effect of reperfusion injury on the endothelial function can be abrogated by ischemic preconditioning.3 Endothelial dysfunction is acknowledged to be the first (subclinical) manifestation of atherosclerosis and cardiovascular disease.5, 6 It is significantly correlated to occurrence of myocardial infarction and stroke.6 Assessment of the flow mediated dilation of the brachial artery as measure of endothelial (dys)function, is a validated model to research effects of possible protective strategies3, 4 and perform mechanistic experiments4, 7, 8 on IR-injury in humans in vivo.

Several previous studies failed to demonstrate the ability of pharmacological stimuli to mimic the beneficial effects of IP in aging vessels.9 Restoration of the age-related reduction in effectiveness of IP may be possible through exercise training. Indirect evidence indicates that physical activity, independent of other cardiovascular risk factors, protects against an occurrence as well as the severity of a myocardial infarction in humans.10 Although this suggests that physical activity may beneficially influence the age-related reduction in IP, no previous study provided direct evidence for this hypothesis in humans.

In this cross-sectional observational experiment we will study the impact of aging (young versus older subjects) and physical fitness (sedentary versus trained older subjects) on the protective effects of ischaemic preconditioning on brachial artery endothelial function after ischaemia-reperfusion injury in healthy humans in vivo.

We hypothesize that aging is associated with an attenuated ability of ischaemic preconditioning to prevent the decrease in brachial artery endothelial function observed after ischaemia reperfusion injury. Moreover, we expect that the age-related reduction in effectiveness of ischaemic preconditioning to prevent endothelial dysfunction after reperfusion injury is (at least partly) preserved in trained older subjects.

Being tested
IPC
Medical subject headings
Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • IPCOther

    repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)

Study groups in NCT01606410
Study groupRoleWhat they receive
young, sedentaryNot described
Receives: Other: IPC
young, activeNot described
Receives: Other: IPC
old, sedentaryNot described
Receives: Other: IPC
old, activeNot described
Receives: Other: IPC

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. endothelial reperfusion injury

    Change in endothelial function (measured with flow mediated dilation) after ischaemia reperfusion injury (induced by 20 minutes ischemia) with and without precedence of ischaemic preconditioning (by 3 cycles of 5-minutes of ischaemia).

    Measured: cross-sectional observation (single time point)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 May 2012 (estimated)
  2. Study startApr 2011
  3. Primary completionNov 2013
  4. Study completionNov 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01606410
Sponsor's protocol ID
IRI-IPC-aging
Status last verified
Nov 2013
First submitted
23 May 2012
Last updated
20 Nov 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cardiovascular Disease, run by Radboud University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

endothelial reperfusion injury (time frame: cross-sectional observation (single time point)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in